In this view, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), by providing an additional benefit of weight loss [9], would represent a preferable second-line option for patients with obesity and inadequately controlled diabetes, as adjunct to lifestyle interventions and metformin [10]. The gene discussed is GCG; the disease is obesity disorder.